Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04490096 · ClinicalTrials.gov registry record · Phase 1
Multimodal Imaging Outcome Measures for ALS (Image ALS)
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04490096: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT04490096 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04490096, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine whether longitudinal neuroimaging acquired across multiple research and clinical centers is a feasible biomarker to use as an outcome measure for clinical trials in amyotrophic lateral sclerosis (ALS)
Primary Outcome
Volume measurement (cubic mm) of brain regions using MRI for ALS patients and healthy controls.
Interventions
- DRUG [11C]-PBR28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-03-17 |
| Phase | Phase 1 |
Why NCT04490096 stopped before completion
NCT04490096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which [11C]-PBR28 is the first listed.
NCT04490096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04490096 about?
NCT04490096 is a clinical study titled "Multimodal Imaging Outcome Measures for ALS (Image ALS)". The primary aim of this study is to determine whether longitudinal neuroimaging acquired across multiple research and clinical centers is a feasible biomarker to use as an outcome measure for clinical trials in amyotrophic lateral sclerosis (ALS)
What is the current status of trial NCT04490096?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-02-25. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT04490096?
The interventions under investigation include: [11C]-PBR28 (DRUG).
Who is sponsoring clinical trial NCT04490096?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04490096's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI